tbuckley/cabot-search huggingface dataset:
EP07.04-23 Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer
Authors: K. Hoshi, S. Togo, I. Sumiyoshi, K. Abe, S. Saiwaki, Y. Hashim, S. Nojiri, Y. Tabe, Y. Urata, K. Takahashi
Journal: Journal of Thoracic Oncology (2023)
EP12.02-04 The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China
Authors: None Y. Ge, None W. Gong, J. Li, J. Wang, X. Wei, S. Wang, Q. Chen, H. Sun, Y. Sun, L. Wang, J. Wu, Y. Sun, A. Gao
Journal: Journal of Thoracic Oncology (2023)
MA21.03 Preoperative Assessment of N2 Mediastinal Lymph Nodes in Non-small Cell Lung Cancer Using Ga-68 FAPI PET/CT: A Prospective Pilot Study
Authors: K.J. Na, Y.-K. Kang, J. Park, N. Kwak, H. Choi, Y.T. Kim
Journal: Journal of Thoracic Oncology (2023)
MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC
Authors: A.H. Nassar, E. Adib, D. Kaldas, J. Feng, T. AbuAli, J. Aredo, B. Fitzgerald, J. Bar, R. Thummalapalli, K. Parikh, R. Whitaker, L. Chen, J. Harris, A. Ayanambakkam, S. Farid, D. Owen, J. Sharp, A.I. Velazquez, M. Ragavan, A. D'aiello, H. Cheng, Z. Piotrowska, M. Wilgucki, J.E. Reuss, T. Patil, Y. Nie, J. Baena Espinar, H. Luders, C. Grohe, K. Sankar, M. Nagasaka, Y.P. Ashara, D.J. Kwiatkowski, R. Mak, A. Amini, A. Lobachov, J.J. Lin, T. Marron, H. Yu, J.W. Neal, H.A. Wakelee, F.A. Shepherd, T.J. Dilling, J.E. Gray, A.R. Naqash, S.B. Goldberg, S.Y. Kim
Journal: Journal of Thoracic Oncology (2023)
P1.13-03 Proof-of-mechanism for a Diagnostic Probe Generating D5-Ethanol Asan On-Breath Reporter Molecule for Lung Cancer - Evolution Phase 1
Authors: M.v.d. Schee, C. Labuschagne, R. Smith, M. Leal, B. Boyle, M. Allsworth, P. Crosbie, R. Rintoul
Journal: Journal of Thoracic Oncology (2023)
P2.01-07 Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE)
Authors: S. Lin, Y. Liu, B.S. Tidwell, P.F. Thall, S. Chun, J.Y. Chang, Z. Liao, Z. Lee, M. Marcondes, M. Tagliaferri, G. Blumenschein, J.V. Heymach, M. Altan, J. Tu
Journal: Journal of Thoracic Oncology (2023)
EP02.01-09 Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma
Authors: M. Ito, Y. Miyata, S. Hirano, N. Morihara, F. Irisuna, M. Takemoto, Y. Tsutani, M. Okada
Journal: Journal of Thoracic Oncology (2023)
P2.31-02 Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution
Authors: R. Hsu, D. Poei, M. Macdonald, R. Diep, A. Leyba, K. Chennapan, C. Leon, K.A. Miller, B.J. Gitlitz, G.K. In, J. Thomas, B. Xia, J. Hu, J.J. Nieva
Journal: Journal of Thoracic Oncology (2023)
P2.15-01 Priming SCLC Vasculature to Facilitate NK Cell Attack
Authors: M. Campisi, C. Stornante, M. Tarannum, S.R. Park, P. Lizotte, S. Kivlehan, J. Wolff, V. Chiono, M. Sheffer, R. Romee, M. Tolstorukov, S. Rodig, C. Paweletz, D.A. Barbie, N.R. Mahadevan
Journal: Journal of Thoracic Oncology (2023)
EP07.01-09 Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients?
Authors: S. Ricciardi, D. Alunni Fegatelli, S. Volpi, F. Femia, L. Petrella, A. Bille, G. Cardillo
Journal: Journal of Thoracic Oncology (2023)
EP04.04-07 The Frequency of Incidental Lung Cancer Detected in Thorax CT During the COVID-19 Pandemic Process in Turkey
Authors: B. Komurcuoglu, M.A. Turk, O. Batum, S. Susam, B. Salik, G. Balci, E. Tellioglu, F. Guldaval, M. Gayaf, F. Demirci, N. Aksel, A. Mertoglu
Journal: Journal of Thoracic Oncology (2023)
EP03.05-02 Genomic Landscape Features of Minimally Invasive Adenocarcinoma and Invasive Lung Adenocarcinoma
Authors: B. Liu, F. Du, D. Wang, Z. Shi, F. Chen, H. Li, D. Li, C. Liu, Y. Zhang, F. Meng, P. Du, L. Li
Journal: Journal of Thoracic Oncology (2023)
EP11.03-26 Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression
Authors: K. Parikh, K. Leventakos, A.S. Mansfield, A. Dimou, J.R. Molina, J. Ambrose, C. Bai, E. Hansen, A. Barcellos, C. Zettler, A. Belli, L. Fernandes, C.-K. Wang
Journal: Journal of Thoracic Oncology (2023)
Author Correction: Single-nucleus multiregion transcriptomic analysis of brain vasculature in Alzheimer’s disease
Authors: Na Sun, Leyla Anne Akay, Mitchell H. Murdock, Yongjin Park, Fabiola Galiana-Melendez, Adele Bubnys, Kyriaki Galani, Hansruedi Mathys, Xueqiao Jiang, Ayesha P. Ng, David A. Bennett, Li-Huei Tsai, Manolis Kellis
Journal: Nature Neuroscience (2023)
Breast cancer immunopeptidomes contain numerous shared tumor antigens
Authors: Eralda Kina, Jean-Philippe Laverdure, Chantal Durette, Joël Lanoix, Mathieu Courcelles, Qingchuan Zhao, Anca Apavaloaei, Jean-David Larouche, Marie-Pierre Hardy, Krystel Vincent, Patrick Gendron, Leslie Hesnard, Catherine Thériault, Maria Virginia Ruiz Cuevas, Grégory Ehx, Pierre Thibault, Claude Perreault
Journal: Journal of Clinical Investigation (2023)

Hormone receptor-positive breast cancer (HR+) is immunologically cold and has not benefited from advances in immunotherapy. In contrast, subsets of triple-negative breast cancer (TNBC) display high leukocytic infiltration and respond to checkpoint blockade. CD8+ T cells, the main effectors of anticancer responses, recognize MHC I-associated peptides (MAPs). Our work aimed to characterize the repertoire of MAPs presented by HR+ and TNBC tumors. Using mass spectrometry, we identified 57,094 unique MAPs in 26 primary breast cancer samples. MAP source genes highly overlapped between both subtypes. We identified 25 tumor-specific antigens (TSAs) mainly deriving from aberrantly expressed regions. TSAs were most frequently identified in TNBC samples and were more shared among The Cancer Genome Atlas (TCGA) database TNBC than HR+ samples. In the TNBC cohort, the predicted number of TSAs positively correlated with leukocytic infiltration and overall survival, supporting their immunogenicity in vivo. We detected 49 tumor-associated antigens (TAAs), some of which derived from cancer-associated fibroblasts. Functional expansion of specific T cell assays confirmed the in vitro immunogenicity of several TSAs and TAAs. Our study identified attractive targets for cancer immunotherapy in both breast cancer subtypes. The higher prevalence of TSAs in TNBC tumors provides a rationale for their responsiveness to checkpoint blockade.
Balance of Gata3 and Ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration
Authors: Bibo Wang, Hao Shen, Yating Wei, Fuchen Liu, Yuan Yang, Han Yu, Jing Fu, Xiuliang Cui, Ting Yu, Ying Xu, Yitian Liu, Hui Dong, Feng Shen, Weiping Zhou, Hui Liu, Yao Chen, Hongyang Wang
Journal: Journal of Hepatology (2023)
Nanomedicines to treat rare neurological disorders: The case of Krabbe disease
Authors: Thomas Lee Moore, Giovanna Pannuzzo, Gabriella Costabile, Anna Lisa Palange, Raffaele Spanò, Miguel Ferreira, Adriana Carol Eleonora Graziano, Paolo Decuzzi, Venera Cardile
Journal: Advanced Drug Delivery Reviews (2023)

The brain remains one of the most challenging therapeutic targets due to the low and selective permeability of the blood-brain barrier and complex architecture of the brain tissue. Nanomedicines, despite their relatively large size compared to small molecules and nucleic acids, are being heavily investigated as vehicles to delivery therapeutics into the brain. Here we elaborate on how nanomedicines may be used to treat rare neurodevelopmental disorders, using Krabbe disease (globoid cell leukodystrophy) to frame the discussion. As a monogenetic disorder and lysosomal storage disease affecting the nervous system, the lessons learned from examining nanoparticle delivery to the brain in the context of Krabbe disease can have a broader impact on the treatment of various other neurodevelopmental and neurodegenerative disorders. In this review, we introduce the epidemiology and genetic basis of Krabbe disease, discuss current in vitro and in vivo models of the disease, as well as current therapeutic approaches either approved or at different stage of clinical developments. We then elaborate on challenges in particle delivery to the brain, with a specific emphasis on methods to transport nanomedicines across the blood-brain barrier. We highlight nanoparticles for delivering therapeutics for the treatment of lysosomal storage diseases, classified by the therapeutic payload, including gene therapy, enzyme replacement therapy, and small molecule delivery. Finally, we provide some useful hints on the design of nanomedicines for the treatment of rare neurological disorders.
Ligand selectivity hotspots in serotonin GPCRs
Authors: Icaro A. Simon, Walden E. Bjørn-Yoshimoto, Kasper Harpsøe, Stylianos Iliadis, Bo Svensson, Anders A. Jensen, David E. Gloriam
Journal: Trends in Pharmacological Sciences (2023)

Serotonin is a neurotransmitter regulating numerous physiological processes also modulated by drugs, for example, schizophrenia, depression, migraine, and obesity. However, these drugs typically have adverse effects caused by promiscuous binding across 12 serotonin and more than 20 homologous receptors. Recently, structures of the entire serotonin receptor family uncovered molecular ligand recognition. Here, we present a map of 19 'selectivity hotspots', that is, nonconserved binding site residues governing selectivity via favorable target interactions or repulsive 'off-target' contacts. Furthermore, we review functional rationale from observed ligand-binding affinities and mutagenesis effects. Unifying knowledge underlying specific probes and drugs is critical toward the functional characterization of different receptors and alleviation of adverse effects.
Insights into highly engraftable hematopoietic cells from 27-year cryopreserved umbilical cord blood
Authors: Hal E. Broxmeyer, Larry L. Luchsinger, Rona Singer Weinberg, Alexandra Jimenez, Emeline Masson Frenet, Wouter van’t Hof, Maegan L. Capitano, Christopher D. Hillyer, Mark H. Kaplan, Scott Cooper, James Ropa
Journal: Cell Reports Medicine (2023)

Umbilical cord blood transplantation is a life-saving treatment for malignant and non-malignant hematologic disorders. It remains unclear how long cryopreserved units remain functional, and the length of cryopreservation is often used as a criterion to exclude older units. We demonstrate that long-term cryopreserved cord blood retains similar numbers of hematopoietic stem and progenitor cells compared with fresh and recently cryopreserved cord blood units. Long-term cryopreserved units contain highly functional cells, yielding robust engraftment in mouse transplantation models. We also leverage differences between units to examine gene programs associated with better engraftment. Transcriptomic analyses reveal that gene programs associated with lineage determination and oxidative stress are enriched in high engrafting cord blood, revealing potential molecular markers to be used as potency markers for cord blood unit selection regardless of length of cryopreservation. In summary, cord blood units cryopreserved for extended periods retain engrafting potential and can potentially be used for patient treatment.
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms
Authors: Sören Reinke, Eirini Pantazi, Gabrielle R. Chappell, Alexandra Sanchez-Martinez, Romain Guyon, Joannah R. Fergusson, Ahmed M. Salman, Anjum Aktar, Ekta Mukhopadhyay, Roland A. Ventura, Floriane Auderset, Patrice M. Dubois, Nicolas Collin, Adrian V.S. Hill, Jelena S. Bezbradica, Anita Milicic
Journal: Cell Reports Medicine (2023)

Adjuvanted protein vaccines offer high efficacy, yet most potent adjuvants remain proprietary. Several adjuvant compounds are being developed by the Vaccine Formulation Institute in Switzerland for global open access clinical use. In the context of the R21 malaria vaccine, in a mouse challenge model, we characterize the efficacy and mechanism of action of four Vaccine Formulation Institute adjuvants: two liposomal (LQ and LMQ) and two squalene emulsion-based adjuvants (SQ and SMQ), containing QS-21 saponin (Q) and optionally a synthetic TLR4 agonist (M). Two R21 vaccine formulations, R21/LMQ and R21/SQ, offer the highest protection (81%–100%), yet they trigger different innate sensing mechanisms in macrophages with LMQ, but not SQ, activating the NLRP3 inflammasome. The resulting in vivo adaptive responses have a different TH1/TH2 balance and engage divergent innate pathways while retaining high protective efficacy. We describe how modular changes in vaccine formulation allow for the dissection of the underlying immune pathways, enabling future mechanistically informed vaccine design.
Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling
Authors: D. A. Dixon
Journal: Journal of Clinical Investigation (2006)

Tight regulation of COX-2 expression is a key feature controlling eicosanoid production in atherosclerosis and other inflammatory syndromes. Adhesive interactions between platelets and monocytes occur in these conditions and deliver specific signals that trigger inflammatory gene expression. Using a cellular model of monocyte signaling induced by activated human platelets, we identified the central posttranscriptional mechanisms that regulate timing and magnitude of COX-2 expression. Tethering of monocytes to platelets and to purified P-selectin, a key adhesion molecule displayed by activated platelets, induces NF-κB activation and COX-2 promoter activity. Nevertheless, COX-2 mRNA is rapidly degraded, leading to aborted protein synthesis. Time-dependent signaling of monocytes induces a second phase of transcript accumulation accompanied by COX-2 enzyme synthesis and eicosanoid production. Here, generation of IL-1β, a proinflammatory cytokine, promoted stabilization of COX-2 mRNA by silencing of the AU-rich mRNA decay element (ARE) in the 3′-untranslated region (3'UTR) of the mRNA. Consistent with observed mRNA stabilization, activated platelets or IL-1β treatment induced cytoplasmic accumulation and enhanced ARE binding of the mRNA stability factor HuR in monocytes. These findings demonstrate that activated platelets induce COX-2 synthesis in monocytes by combinatorial signaling to transcriptional and posttranscriptional checkpoints. These checkpoints may be altered in disease and therefore useful as targets for antiinflammatory intervention.
EP12.01-26 Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations
Authors: F. Shao, Q. Zhang, W. Cheng, N. Liu, H. Fang, S. Fang
Journal: Journal of Thoracic Oncology (2023)
PL03.07 Invasion or No Invasion, That’s the Question. A Large Reproducibility Study in Pulmonary Adenocarcinoma, Supporting a Modified Classification
Authors: E. Thunnissen, H. Blaauwgeers, F. Filipello, B. Lissenberg-Witte, Y. Minami, M. Noguchi, J. Le Quense, M.G. Papotti, D. Flieder, G. Pelosi, I. Sansano, S. Berezowska, A. Ryška, L. Brcic, N. Motoi, Y. Nakatani, C. Kuempers, P. Hofman, V. Hofman, V. Grotnes Dale, G. Rossi, F. Ambrosi, D. Matsubara, Y. Ishikawa, B. Weynand, F. Calabrese, F. Pezzuto, I. Kern, S. Nicholson, A.-L. Mutka, S. Dacic, M.B. Beasley, G. Arrigoni, W. Timens, M. Ooft, M. Brinkhuis, N. Bulkmans, R. Britstra, W. Vreuls, K. Jones, J. von der Thüsen, H. Hager, S. Perner, D. Moore, D.G. Leonte, S. Al-Janabi, A. Schønau, A. Stenzinger, D. Kazdal
Journal: Journal of Thoracic Oncology (2023)
OA12.06 Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
Authors: J. He, S. Gao, M. Reck, D. Harpole, T. Mitsudomi, J.M. Taube, K.-Y. Lee, Y. Horio, Y. Runglodvatana, M. Aperghis, G.J. Doherty, P.J. Laud, T.M. Fouad, J.V. Heymach
Journal: Journal of Thoracic Oncology (2023)
The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair
Authors: Xiaoxue Li, Aiting Liu, Chen Xie, Yanlian Chen, Kuan Zeng, Changming Xie, Zhengzhipeng Zhang, Pei Luo, Hui Huang
Journal: Kidney International (2023)
MA17.03 Determining the Clinical Utility of a Breath Test to Screen Asbestos-Exposed Persons for Pleural Mesothelioma
Authors: K. Lamote, K. Zwijsen, E. Schillebeeckx, J. Van Cleemput, C. Jonckheere, T. Richart, V. Surmont, K. Nackaerts, E. Marcq, J.P. van Meerbeeck
Journal: Journal of Thoracic Oncology (2023)
EP12.01-54 Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam
Authors: C.T.M. Pham, T.T.A. Hoang, P.T. Truong, P.T.T. Bui, T.T. Nguyen, T.N. Vo, D.T. Tran, D.T. Nguyen, T.X. Tran, H.H. Le, H.Q. Dong, K.T. Nguyen
Journal: Journal of Thoracic Oncology (2023)
Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam
Authors: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol
Journal: European Urology (2023)

Background: The optimal timing for discontinuing screening of prostate cancer (PCa) in elderly men is currently not known and remains debated.Objective: To assess prostate cancer-specific mortality (PCSM) in elderly men who previously underwent prostate-specific antigen (PSA)-based screening and to identify those who may benefit from continued screening.Design, setting, and participants: A total of 7052 men, who participated in the screening arm of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer and were aged 70-74 yr at their last screening visit after undergoing a maximum of three screening rounds without being diagnosed with PCa, were included.Outcome measurements and statistical analysis: The cumulative incidence of PCSM by the age of 85 yr was assessed.Additionally, a competing risk regression was performed to assess the potential predictors of PCSM.Results and limitations: The median follow-up was 16 yr.The cumulative incidence of PCSM by the age of 85 yr was 0.54% (95% confidence interval [CI]: 0.40-0.70) in all men, 0.11% (95% CI: 0.05-0.27) in men with PSA <2 ng/ml, 0.85% (95% CI: 0.47-1.5) in men with PSA 2-3 ng/ml, and 6.8% (95% CI: 3.1-15) in men with PSA 6.5 ng/ml and no previous benign biopsy.PSA (subdistribution hazard ratio [sHR]: 2.0; 95% CI: 1.7-2.3),previous benign prostate biopsy (sHR: 0.41; 95% CI: 0.23-0.72),and hypertension (sHR: 0.48; 95% CI: 0.25-0.91)were significantly associated with PCSM.Conclusions: Men aged 70-74 yr who have previously undergone PSA-based screening without receiving a PCa diagnosis have a very low risk of dying from PCa by the age of 85 yr.These data suggest that screening may be discontinued in men with PSA <3.0 ng/ml or previous benign prostate biopsies.Those with higher PSA levels and no prior biopsies may consider continued screening if life expectancy exceeds 10 yr.
Transbronchial lung cryobiopsy for peripheral pulmonary lesions. A narrative review
Authors: Y. Tang, S. Tian, H. Chen, X. Li, X. Pu, X. Zhang, Y. Zheng, Y. Li, H. Huang, C. Bai
Journal: Pulmonology (2023)

An increasing number of peripheral pulmonary lesions (PPLs) requiring tissue verification to establish a definite diagnosis for further individualized management are detected due to the growing adoption of lung cancer screening by chest computed tomography (CT), especially low-dose CT. However, the morphological diagnosis of PPLs remains challenging. Transbronchial lung cryobiopsy (TBLC) that can retrieve larger specimens with more preserved cellular architecture and fewer crush artifacts in comparison with conventional transbronchial forceps biopsy (TBFB), as an emerging technology for diagnosing PPLs, has been demonstrated to have the potential to resolve the clinical dilemma pertaining to currently available sampling devices (e.g., forceps, needle and brush) and become a diagnostic cornerstone for PPLs. Of note, with the introduction of the 1.1 mm cryoprobe that will be more compatible with advanced bronchoscopic navigation techniques, such as radial endobronchial ultrasound (r-EBUS), virtual bronchoscopic navigation (VBN) and electromagnetic navigation bronchoscopy (ENB), the use of TBLC is expected to gain more popularity in the diagnosis of PPLs. While much remains for exploration using the TBLC technique for diagnosing PPLs, it can be envisaged that the emergence of additional studies with larger data accrual will hopefully add to the body of evidence in this field.
OA17.05 Association Between Pre-Treatment Circulating Immune Biomarkers And Survival In Stage III NSCLC: A Translational Analysis From NRG-RTOG 0617
Authors: M. Machtay, C. Hu, T.D. Schell, J.D. Bradley, G.H. Perdew, B. Lu, L. Beidler, F. Dong, R.C. Jordan, S. DeVries, M. Werner Wasik, Y.I. Garces, S. Narayan, C.G. Robinson, J.M. Rothman, A. Raben, V.S. Kavadi, E.M. Gore, T. Wu, F.-M. Kong
Journal: Journal of Thoracic Oncology (2023)
OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer
Authors: I. Houda, I. Bahce, C. Dickhoff, T.E. Kroese, S.G.C. Kroeze, A.V. Mariolo, M. Tagliamento, L. Moliner, M. Brandao, J. Edwards, I. Opitz, C. Faivre-Finn, D. de Ruysscher, J. Remon, T. Berghmans, A.-M.C. Dingemans, B. Besse, L.E.L. Hendriks
Journal: Journal of Thoracic Oncology (2023)
MA15.11 A Phase I/II Study of TQ-B2450 plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies: Phase II Results Updates
Authors: M. Shi, P. Chen, L. Cui, Y. Yao, J. Wang, T. Zhou, J. Feng
Journal: Journal of Thoracic Oncology (2023)
OA19.03 Exportin 1 Inhibition Constraints Lineage Plasticity and Histological Transformation through Downregulation of SOX2
Authors: A. Quintanal-Villalonga, V. Durani, A. Sabet, E. Redin, K. Kawasaki, M. Shaffer, P. Manoj, H. Sridhar, M.C. Haffner, C.L. Sawyers, C.M. Rudin
Journal: Journal of Thoracic Oncology (2023)
OA12.04 Nivolumab After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial
Authors: J.Y. Chang, S.H. Lin, W. Dong, Z. Liao, S. Gandhi, S.G. Chun, C.M. Gay, J. Zhang, F.V. Fossella, G.R. Blumenschein, T. Cascone, X. Le, J.V. Pozadzides, A. Tsao, A. Mehmet, J.W. Welsh, V. Verma, I.I. Wistuba, J. Lee, J. Heymach
Journal: Journal of Thoracic Oncology (2023)